Advanced search
Publication Cover
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration Volume 23, 2022 - Issue 1-2
Submit an article Journal homepage
1,867
Views
3
CrossRef citations to date
0
Altmetric
Clinical

Evidence for generalizability of edaravone efficacy using a novel machine learning risk-based subgroup analysis tool

Benjamin Rix Brooks1 Carolinas Neuromuscular/ALS-MDA Care Center, Charlotte, NC, USAView further author information
,
Erik P. Pioro2 Section of ALS & Related Disorders, Cleveland Clinic, Cleveland, OH, USAView further author information
,
Danielle Beaulieu3 Origent Data Sciences, Inc., Vienna, VA, USA, andView further author information
,
Albert A. Taylor3 Origent Data Sciences, Inc., Vienna, VA, USA, andView further author information
,
Mark Schactman3 Origent Data Sciences, Inc., Vienna, VA, USA, andView further author information
,
Mike Keymer3 Origent Data Sciences, Inc., Vienna, VA, USA, andView further author information
,
Wendy Agnese4 Mitsubishi Pharma America, Inc., Jersey City, NJ, USAView further author information
,
Johnna Perdrizet4 Mitsubishi Pharma America, Inc., Jersey City, NJ, USAView further author information
,
Stephen Apple4 Mitsubishi Pharma America, Inc., Jersey City, NJ, USACorrespondence[email protected]
View further author information
&
David L. Ennist3 Origent Data Sciences, Inc., Vienna, VA, USA, andView further author information
 show all
Pages 49-57 | Received 27 Oct 2020, Accepted 25 Apr 2021, Published online: 10 Jul 2021

References

  • Brown RH, Al-Chalabi A. Amyotrophic lateral sclerosis. N Engl J Med. 2017;377:162–72.
  • G. B. D. Motor Neuron Disease Collaborators. Global, regional, and national burden of motor neuron diseases 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2018;17:1083–97.
  • Oskarsson B, Gendron TF, Staff NP. Amyotrophic lateral sclerosis: an update for 2018. Mayo Clin Proc. 2018;93:1617–28.
  • Kiernan MC, Vucic S, Cheah BC, Turner MR, Eisen A, Hardiman O, et al. Amyotrophic lateral sclerosis. Lancet. 2011;377:942–55.
  • Miller RG, Jackson CE, Kasarskis EJ, England JD, Forshew D, Johnston W, Quality Standards Subcommittee of the American Academy of Neurology, et al. Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: drug, nutritional, and respiratory therapies (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2009;73:1218–26.
  • Radicava® (edaravone injection) [package insert]. Jersey City, NJ: Mitsubishi Tanabe Pharma Corporation; August 2018.
  • Rilutek® (riluzole) [package insert]. Bridgewater, NJ: sanofi-aventis U.S. LLC; November 2012.
  • Miller RG, Mitchell JD, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev. 2012;2012:CD001447.
  • Writing Group; Edaravone (MCI-186) ALS 19 Study Group. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2017;16:505–12.
  • Mitsumoto H, Brooks BR, Silani V. Clinical trials in amyotrophic lateral sclerosis: why so many negative trials and how can trials be improved? Lancet Neurol. 2014;13:1127–38.
  • Palumbo JM, Hubble J, Apple S, Takei K, Tsuda K, Liu S, et al. Post-hoc analyses of the edaravone clinical trials Study 16 and Study 19: a step toward more efficient clinical trial designs in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2019;20:421–31.
  • Abe K, Itoyama Y, Sobue G, Tsuji S, Aoki M, Doyu M, Edaravone ALS Study Group, et al. Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients. Amyotroph Lateral Scler Frontotemporal Degener. 2014;15:610–7.
  • Edaravone (MCI-186) ALS 16 Study Group. A post-hoc subgroup analysis of outcomes in the first phase III clinical study of edaravone (MCI-186) in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18:11–9.
  • Beaulieu D, Taylor AA, Pierce D, Cuerdo J, Schactman M, Keymer M, et al. Chapter 14 – Improving clinical trial efficiency with machine learning models of disease progression. In: Smith RA, Kaspar BK, Svendsen CN, eds. Neurotherapeutics in the Era of Translational Medicine. Academic Press; 2021:333–66. ISBN 9780128164754.
  • Shefner JM, Wolff AA, Meng L, Bian A, Lee J, Barragan D, BENEFIT-ALS Study Group, et al. A randomized, placebo-controlled, double-blind phase IIb trial evaluating the safety and efficacy of tirasemtiv in patients with amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2016;17:426–35.
  • Agnese W, Apple S, Liu S, Zhang J, Hubble J. A post-hoc analysis of edaravone study 19: Forced vital capacity (FVC) subgroup analysis. European Network to Cure ALS (ENCALS) 2018 Meeting; 20–22 June 2018; Oxford, UK. Abstract D31.
  • Van Eijk RPA, Westeneng H-J, Nikolakopoulos S, Verhagen IE, van Es MA, Eijkemans MJC, et al. Refining eligibility criteria for amyotrophic lateral sclerosis clinical trials. Neurology. 2019;92:e451–60.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.